C4 Therapeutics, Inc. (CCCC) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$3.30

From 52W high−33.19%

Volume1.97M

Market cap$383.84M

P/E (TTM)—

P/S (TTM)11.0x

Div yield—

Key dataNov 4, 2026

Open

$3.30

From 52W high

−33.19%

Volume

1.97M

Market cap

$383.84M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

P/E (TTM)

—

RSI (14)

46.1

MomentumView details →

1D Return

−2.80%

YTD Return

+58.90%

SummaryUpdated Jun 1, 2026

C4 Therapeutics, Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in October 2020 and focuses on developing innovative cancer treatments using a novel approach called targeted protein degradation. C4 Therapeutics has established strategic partnerships with major pharmaceutical companies including Roche, Biogen, and Calico Life Sciences to advance its pipeline of experimental drugs through clinical trials.

Ask drillr about C4 Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.9x

EV/Sales

5.3x

P/S (TTM)

11.0x

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

94.86%

Net Margin

−289.44%

EBITDA Margin

−284.57%

ROE (TTM)

−41.02%

ROA (TTM)

−28.22%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

+2.33%

EPS YoY

+36.71%

FCF YoY

+2.49%

Revenue CAGR 3Y

+4.95%

EPS CAGR 3Y

+16.45%

EBITDA YoY

+6.42%

MomentumView details →

1D Return

−2.80%

YTD Return

+58.90%

1Y Return

+28.06%

RSI (14)

46.1

vs 50D SMA

−7.08%

vs 200D SMA

−5.79%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

5.45x

Quick Ratio

5.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

20.49%

Beats (12Q)

8/12

Next Q EPS Est

−$0.26

Avg Surprise (4Q)

12.43%

Rev Surprise

66.03%

Financials snapshotView financials →

Revenue (TTM)

35.04M

Net Income (TTM)

−101.42M

Op. CF (TTM)

−84.87M

Next earningsNov 5, 2026 →

Latest newsMore news →

C4 Therapeutics, Inc. reported a Q2 loss of $0.18 per share, beating the Zacks Consensus Estimate of a loss of $0.23 and improving from a loss of $0.37 per share a year ago.85d ago

Similar companies

Contineum Therapeutics, Inc. Class A Common StockCTNM Rezolute, Inc.RZLT Zura Bio LimitedZURA Avalo Therapeutics, Inc.AVTX Lyell Immunopharma, Inc.LYEL Uni-Bio Science Group Limited00690.HK Find similar companies →

Latest newsMore news →

C4 Therapeutics, Inc. reported a Q2 loss of $0.18 per share, beating the Zacks Consensus Estimate of a loss of $0.23 and improving from a loss of $0.37 per share a year ago.85d ago